- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 108 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| 05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| 25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 513 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health announces distribution agreement with Virax Biolabs | 3 | Seeking Alpha | ||
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 366 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 23.09.24 | Cosmos Health Inc: Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits | 244 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 16.09.24 | Cosmos Health Inc.: Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar | 282 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 28.08.24 | Pre-market Movers: Bolt Projects, Acri Capital Acquisition, JBDI, Virax Biolabs, Ambarella | 1.014 | AFX News | SAINT PAUL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Bolt Projects Holdings, Inc. (BSLK) is up over... ► Artikel lesen | |
| 21.08.24 | Cosmos Health Inc.: Cosmos Health Holds EU Distribution Rights for Virax Biolabs' Mpox Virus Real-Time PCR Detection Kits | 498 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / August 21, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | BioNTech-Aktie: Merkwürdiges Kursverhalten | © Foto: SymbolbildDer steinige Weg vom Corona-Helden zum Krebs-Jäger. So hätte auch die Überschrift lauten können, denn die Mainzer sorgen derzeit für Aufsehen mit Übernahmen und Kooperationen. Einmal... ► Artikel lesen | |
| EVOTEC | 7,138 | -0,81 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
| BAVARIAN NORDIC | 22,640 | -0,70 % | Bavarian Nordic A/S: Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women | First studies to evaluate MVA-BN in infants under 2 years of age and pregnant and breastfeeding women.The multi-partner research project is aimed at expanding access to mpox vaccines for vulnerable... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 5,592 | +3,14 % | Emergent lands $62.4M upgrade to botulism antitoxin supply pact with US | ||
| GINKGO BIOWORKS | 7,750 | -3,73 % | Ginkgo Bioworks stock rises on Hugging Face collaboration for AI drug development | ||
| GENPREX | 1,820 | -100,00 % | Genprex, Inc. - 8-K, Current Report | ||
| PALISADE BIO | 0,720 | +0,87 % | Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis | Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | Gritstone bio, Inc. - 15-12G, Securities registration termination | ||
| SIGA TECHNOLOGIES | 6,465 | -1,60 % | SIGA Reports Record Profits for Latest Fiscal Year | ||
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - S-1/A, General form for registration of securities | ||
| ANNOVIS BIO | 1,782 | -1,22 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| HUMACYTE | 2,115 | -4,73 % | Humacyte, Inc: Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update | - Commenced market launch and first commercial sales of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 6,550 | -2,24 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to... ► Artikel lesen |
Das Unternehmen VIRAX BIOLABS GROUP LIMITED kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,780 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.